IRWD Ironwood Pharmaceuticals, Inc. - Class A Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
14:31
Jan 16
Jan 16
Linzess sales beat and pediatric label expansion drive upside
Linzess Q3 sales came in well above expectations (~$315–350M vs ~$250M), and Ironwood receives ~33% of those sales, adding roughly $80M annually above prior expectations. FDA label expansion for pediatric use makes Linzess the first drug for that indication, expanding the addressable market with limited competition. The upcoming quarterly report and pipeline updates are the next catalyst, with the author seeing mostly upside and potential 2x-3x in the next 6 months.
HIGH
About IRWD Investor Commentary
Across the available history and selected sources, Buzzberg tracks IRWD (Ironwood Pharmaceuticals, Inc. - Class A) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/zinc_finger_protein.